No Data
No Data
Piper Sandler Maintains Immatics(IMTX.US) With Buy Rating, Maintains Target Price $19
Analysts Conflicted on These Healthcare Names: AnaptysBio (ANAB), Stoke Therapeutics (STOK) and Immatics (IMTX)
Immatics N.V. (NASDAQ:IMTX) Is a Favorite Amongst Institutional Investors Who Own 50%
Perceptive Advisors LLC Reduces Stake in Immatics NV
6-K: Report of foreign private issuer (related to financial reporting)
Buy Rating Affirmed for Immatics Amidst Promising Clinical Trials and Strategic Positioning in TCR Therapeutics